

Turn Bio signs agreement with Korea's HanAll Biopharma to develop eye and ear therapies

29 May 2024 | News

Deal valued at over \$300 million for initial product



US-based startup Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, has announced an exclusive global licensing agreement with South Korea-based pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions.

The agreement, potentially exceeding \$300 million in value for the first of multiple planned products, significantly expands the relationship between the companies. HanAll originally invested in Turn Bio in 2022.

Products resulting from this collaboration will utilise Turn Bio's Epigenetic Reprogramming of Age (ERA) technology and its novel eTurna delivery platform. These cutting-edge technologies aim to restore optimal gene expression, combatting the effects of aging at the cellular level to treat and potentially cure chronic conditions.

HanAll has closely monitored Turn Bio's progress since its initial investment, recognizing the revolutionary potential of its epigenetic reprogramming technology.

The partnership expands Turn Bio's development, which had primarily focused on dermatology and immunology, to two other organs most commonly affected by age-related conditions. This means Turn Bio is working on therapies to treat and potentially cure most diseases caused by ageing.